Law Offices of Howard G. Smith Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, impacting investors who purchased shares between October 10, 2023, and December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made materially false and misleading statements regarding its business operations and prospects during the class period [1]. - Investors have until April 7, 2026, to file a lead plaintiff motion in the ongoing lawsuit [1]. - The complaint alleges that Inovio failed to disclose significant issues related to its CELLECTRA device manufacturing and the likelihood of timely FDA submission for its INO-3107 treatment [1]. Group 2: Stock Price Impact - Following the announcement of a delay in the BLA submission for INO-3107 due to manufacturing issues, Inovio's stock price fell by $0.27, or 3.1%, closing at $8.44 on August 9, 2024 [1]. - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56, or 24.45%, closing at $1.73 [1]. Group 3: Allegations of Misleading Information - The lawsuit alleges that Inovio overstated the regulatory and commercial prospects of INO-3107, leading to materially misleading statements about the company's business [1]. - Specific allegations include deficiencies in manufacturing for the CELLECTRA device and insufficient information to justify eligibility for FDA accelerated approval [1].